The contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) is a relative new algorithm for hepatocellular carcinoma (HCC) assessment.
OBJECTIVE:
To validate the diagnostic efficiency of the intravascular perfusion based CEUS LI-RADS for HCC.
METHODS:
Archives of 873 patients with focal liver lesions (FLLs) undergoing CEUS were reviewed, and target images were read by two sonologists independently according to the CEUS LI-RADS. The diagnostic performance was calculated and compared.
RESULTS:
Assessment with reference to CEUS LI-RADS, 87 of 218 FLLs (39.9%) were categorized as LR-5, 131 of 218 FLLs (60.1%) were categorized as non-LR-5, 19 of 99 HCCs were categorized as non-LR-5, and 7 of 119 non-HCCs were categorized as LR-5. The sensitivity, specificity, AUROC, positive and negative predictive values of CEUS LI-RADS for diagnosing HCC were 80.81%(95%CI: 71.7%–88.0%), 94.1%(95%CI: 88.3%–97.6%), 0.87 (95%CI: 0.82–0.92), 91.9%(95%CI: 84.1%–96.7%), and 85.5%(95%CI: 78.3%–91.0%), respectively.
CONCLUSIONS:
The diagnostic efficiency of the intravascular perfusion based CEUS LI-RADS for the evaluation of HCCs is very good.
FerlayJ, ColombetM, SoerjomataramI, MathersC, ParkinDM, PiñerosM, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53.
2.
AllemaniC, MatsudaT, Di CarloV, HarewoodR, MatzM, NikšićM, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75.
3.
KulikL, El-SeragHB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156(2):477–91.e1.
4.
HeimbachJK, KulikLM, FinnRS, SirlinCB, AbecassisMM, RobertsLR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.
5.
DietrichCF, NolsøeCP, BarrRG, BerzigottiA, BurnsPN, CantisaniV, et al. Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound Med Biol. 2020;46(10):2579–604.
6.
MarschnerCA, ZhangL, SchwarzeV, VölckersW, FroelichMF, von MünchhausenN, et al. The diagnostic value of contrast-enhanced ultrasound (CEUS) for assessing hepatocellular carcinoma compared to histopathology; a retrospective single-center analysis of 119 patients1. Clin Hemorheol Microcirc. 2020;76(4):453–8.
7.
LyshchikA, KonoY, DietrichCF, JangHJ, KimTK, PiscagliaF, et al. Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group. Abdom Radiol (NY). 2018;43(4):861–79.
8.
WilsonSR, LyshchikA, PiscagliaF, CosgroveD, JangHJ, SirlinC, et al. CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI. Abdom Radiol (NY). 2018;43(1):127–42.
9.
ElsayesKM, KielarAZ, ChernyakV, MorshidA, FurlanA, MaschWR, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma. 2019;6:49–69.
10.
SchellhaasB, GörtzRS, PfeiferL, KielischC, NeurathMF, StrobelD. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS. Eur J Gastroenterol Hepatol. 2017;29(9):1036–44.
11.
TerziE, IavaroneM, PompiliM, VeroneseL, CabibboG, FraquelliM, et al. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. J Hepatol. 2018;68(3):485–92.
12.
LingW, WangM, MaX, QiuT, LiJ, LuQ, et al. The preliminary application of liver imaging reporting and data system (LI-RADS) with contrast-enhanced ultrasound (CEUS) on small hepatic nodules (≤2cm). J Cancer. 2018;9(16):2946–52.
13.
LiJ, LingW, ChenS, MaL, YangL, LuQ, et al. The interreader agreement and validation of contrast-enhanced ultrasound liver imaging reporting and data system. Eur J Radiol. 2019;120:108685.
14.
LiF, LiQ, LiuY, HanJ, ZhengW, HuangY, et al. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017. Eur Radiol. 2020;30(1):461–70.
15.
HuangJY, LiJW, LuQ, LuoY, LinL, ShiYJ, et al. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma. Radiology. 2020;294(2):329–39.
16.
SonJH, ChoiSH, KimSY, JangHY, ByunJH, WonHJ, et al. Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma. Radiology. 2019;292(2):390–7.
17.
Abd Alkhalik BashaM, Abd El Aziz El SammakD, El SammakAA. Diagnostic efficacy of the Liver Imaging-Reporting and Data System (LI-RADS) with CT imaging in categorising small nodules (10-20 mm) detected in the cirrhotic liver at screening ultrasound. Clin Radiol. 2017;72(10):901.e1–901.e11.
18.
YangHK, BurnsPN, JangHJ, KonoY, KhaliliK, WilsonSR, et al. Contrast-enhanced ultrasound approach to the diagnosis of focal liver lesions: the importance of washout. Ultrasonography. 2019;38(4):289–301.
19.
ZhengW, LiQ, ZouXB, WangJW, HanF, LiF, et al. Evaluation of Contrast-enhanced US LI-RADS version 2017: Application on 2020 Liver Nodules in Patients with Hepatitis B Infection. Radiology. 2020;294(2):299–307.
20.
StockerD, BeckerAS, BarthBK, SkawranS, KaniewskaM, FischerMA, et al. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018-based classification of liver lesions?Eur Radiol. 2020;30(5):2922–33.
21.
LandisJR, KochGG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.
22.
ChenLD, RuanSM, LiangJY, YangZ, ShenSL, HuangY, et al. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound. World J Gastroenterol. 2018;24(33):3786–98.
23.
TakahashiM, MaruyamaH, ShimadaT, KamezakiH, SekimotoT, KanaiF, et al. Characterization of hepatic lesions (< /=30mm) with liver-specific contrast agents: a comparison between ultrasound and magnetic resonance imaging. Eur J Radiol. 2013;82(1):75–84.
24.
LeoniS, PiscagliaF, GranitoA, BorghiA, GalassiM, MarinelliS, et al. Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted?Ultraschall Med. 2013;34(3):280–7.
25.
BoozariB, SoudahB, RifaiK, SchneidewindS, VogelA, HeckerH, et al. Grading of hypervascular hepatocellular carcinoma using late phase of contrast enhanced sonography - a prospective study. Dig Liver Dis. 2011;43(6):484–90.
26.
SakamotoM, HirohashiS, ShimosatoY. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol. 1991;22(2):172–8.
27.
KitaoA, ZenY, MatsuiO, GabataT, NakanumaY. Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography–radiologic-pathologic correlation. Radiology. 2009;252(2):605–14.
28.
HanJ, LiuY, HanF, LiQ, YanC, ZhengW, et al. The Degree of Contrast Washout on Contrast-Enhanced Ultrasound in Distinguishing Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma. Ultrasound Med Biol. 2015;41(12):3088–95.
29.
WildnerD, BernatikT, GreisC, SeitzK, NeurathMF, StrobelD. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med. 2015;36(2):132–9.
30.
YuanMX, LiR, ZhangXH, TangCL, GuoYL, GuoDY, et al. Factors Affecting the Enhancement Patterns of Intrahepatic Cholangiocarcinoma (ICC) on Contrast-Enhanced Ultrasound (CEUS) and their Pathological Correlations in Patients with a Single Lesion. Ultraschall Med. 2016;37(6):609–18.
31.
SchaibleJ, StroszczynskiC, BeyerLP, JungEM. Quantitative perfusion analysis of hepatocellular carcinoma using dynamic contrast enhanced ultrasound (CEUS) to determine tumor microvascularization. Clin Hemorheol Microcirc. 2019;73(1):95–104.
32.
BittererF, HornungM, Platz Batista da SilvaN, SchlittHJ, StroszczynskiC, WegeAK, JungEM. In vivo detection of breast cancer liver metastases in humanized tumour mice using tumour specific contrast agent BR55®. Clin Hemorheol Microcirc. 2020;76(4):559–72.
